Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Breast Cancer
Interventions: DRUG: Fulvestrant|DRUG: Neratinib|DRUG: Alpelisib|DRUG: Everolimus|DRUG: Abemaciclib
Sponsor: Dartmouth-Hitchcock Medical Center